CN101400338A - 用于预防糖尿病足截除的微球体药物组合物 - Google Patents

用于预防糖尿病足截除的微球体药物组合物 Download PDF

Info

Publication number
CN101400338A
CN101400338A CNA2007800090345A CN200780009034A CN101400338A CN 101400338 A CN101400338 A CN 101400338A CN A2007800090345 A CNA2007800090345 A CN A2007800090345A CN 200780009034 A CN200780009034 A CN 200780009034A CN 101400338 A CN101400338 A CN 101400338A
Authority
CN
China
Prior art keywords
microspheres
pharmaceutical composition
egf
growth factor
wound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800090345A
Other languages
English (en)
Chinese (zh)
Inventor
B·Y·贝坦克特罗德里格斯
V·M·赛斯马丁内斯
R·佩斯梅雷莱斯
J·A·贝兰加阿科斯塔
J·A·拉蒙埃尔南德斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centro de Ingenieria Genetica y Biotecnologia CIGB
Original Assignee
Centro de Ingenieria Genetica y Biotecnologia CIGB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38185604&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101400338(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centro de Ingenieria Genetica y Biotecnologia CIGB filed Critical Centro de Ingenieria Genetica y Biotecnologia CIGB
Publication of CN101400338A publication Critical patent/CN101400338A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CNA2007800090345A 2006-01-31 2007-01-29 用于预防糖尿病足截除的微球体药物组合物 Pending CN101400338A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU20060021A CU23388B6 (es) 2006-01-31 2006-01-31 Composición farmacéutica de microesferas para prevenir la amputación del pie diabético
CU20060021 2006-01-31

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201410189221.8A Division CN103933552A (zh) 2006-01-31 2007-01-29 用于预防糖尿病足截除的微球体药物组合物

Publications (1)

Publication Number Publication Date
CN101400338A true CN101400338A (zh) 2009-04-01

Family

ID=38185604

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA2007800090345A Pending CN101400338A (zh) 2006-01-31 2007-01-29 用于预防糖尿病足截除的微球体药物组合物
CN201410189221.8A Pending CN103933552A (zh) 2006-01-31 2007-01-29 用于预防糖尿病足截除的微球体药物组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201410189221.8A Pending CN103933552A (zh) 2006-01-31 2007-01-29 用于预防糖尿病足截除的微球体药物组合物

Country Status (24)

Country Link
US (1) US8741848B2 (enExample)
EP (1) EP1987817B1 (enExample)
JP (1) JP5219841B2 (enExample)
KR (1) KR101401273B1 (enExample)
CN (2) CN101400338A (enExample)
AR (1) AR059234A1 (enExample)
AT (1) ATE437631T1 (enExample)
AU (1) AU2007211753B2 (enExample)
BR (1) BRPI0707395A2 (enExample)
CA (1) CA2640743C (enExample)
CU (1) CU23388B6 (enExample)
CY (1) CY1109513T1 (enExample)
DE (1) DE602007001786D1 (enExample)
DK (1) DK1987817T3 (enExample)
ES (1) ES2330688T3 (enExample)
HK (1) HK1198743A1 (enExample)
MY (1) MY143742A (enExample)
PL (1) PL1987817T3 (enExample)
PT (1) PT1987817E (enExample)
RU (1) RU2426528C2 (enExample)
SG (1) SG169366A1 (enExample)
SI (1) SI1987817T1 (enExample)
WO (1) WO2007087759A2 (enExample)
ZA (1) ZA200806648B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23411B6 (es) * 2005-12-29 2009-09-08 Ct Ingenieria Genetica Biotech Uso tópico del factor de crecimiento epidérmico en liposomas para prevenir la amputación del pie diabético
RU2351334C1 (ru) * 2007-12-04 2009-04-10 Георгий Кимович Золоев Способ лечения хронической ишемии нижних конечностей ii б - iv степени
ES2340902B1 (es) 2008-07-01 2011-05-03 Laboratorios Farmaceuticos Rovi, S.A. Composicion farmaceutica con glicosaminoglicanos y su uso en tratamiento de ulceras cronicas.
GB0814302D0 (en) 2008-08-05 2008-10-01 Coretherapix Slu Compounds and methods
KR101156094B1 (ko) * 2010-02-22 2012-06-20 경상대학교산학협력단 약물송달을 위한 양친성 ＰＨＡ－ｍＰＥＧ 공중합 나노 컨테이너
RU2421221C1 (ru) * 2010-03-22 2011-06-20 Государственное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" Способ лечения критической ишемии нижних конечностей различного генеза
RU2425675C1 (ru) * 2010-05-25 2011-08-10 Федеральное государственное учреждение "Нижегородский научно-исследовательский институт травматологии и ортопедии Федерального агентства по высокотехнологичной медицинской помощи" Способ лечения больных с нейропатической и нейроишемической формами синдрома "диабетическая стопа"
ES2357601B1 (es) 2011-01-26 2012-03-21 Laboratorios Farmacéuticos Rovi, S.A. Procedimiento de preparación de derivados de glicosaminoglicanos donadores de óxido n�?trico y su uso en tratamiento de úlceras crónicas.
EP2737895A1 (en) * 2012-11-30 2014-06-04 Praxis Pharmaceutical, S.A. Microparticles with EGF, method of preparation and use
EP2821077A1 (en) 2013-07-04 2015-01-07 Praxis Biopharma Research Institute Lipid nanoparticles for wound healing
EP3097922A1 (fr) 2015-05-28 2016-11-30 Denis Barritault Composition pour le traitement des lesions tissulaires
CN106267163A (zh) * 2015-06-09 2017-01-04 济南博创医药科技有限公司 一种治疗皮肤创伤的药物组合物及其药物制剂
MX389934B (es) * 2016-12-09 2025-03-20 Desarrolladora Y Com De Tecnologias Biomedicas Decotecbio S A De C V Composición coadyuvante de un factor de crecimiento y un neuropéptido para acelerar la cicatrización de heridas y la repitelización de órganos.
KR102218427B1 (ko) * 2017-09-20 2021-02-22 차의과학대학교 산학협력단 단백질 약물을 포함하는 코아세르베이트 조성물 및 이를 포함하는 창상 치료제
CU20190022A7 (es) * 2019-03-18 2020-10-20 Centro De Ingenieria Genetica Y Biotecnologia Biocubafarma Composición farmacéutica para el tratamiento de la úlcera del pie diabético

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
NZ226171A (en) 1987-09-18 1990-06-26 Ethicon Inc Gel formulation containing polypeptide growth factor
JP2670680B2 (ja) * 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
US5034375A (en) 1988-08-10 1991-07-23 Institute Of Molecular Biology, Inc. Process of wound healing using PDGF and EGF
US4944948A (en) 1989-02-24 1990-07-31 Liposome Technology, Inc. EGF/Liposome gel composition and method
EP0465588A4 (en) 1989-04-04 1992-06-03 Alcon Laboratories Inc The use of liposomes for the delivery of therapeutic agents to wounds, cuts and abrasions
US5130298A (en) 1989-05-16 1992-07-14 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
CA2038945A1 (en) 1989-08-01 1991-02-02 Norman D. Weiner Topical delivery of peptides/proteins entrapped in dehydration/rehydration liposomes
AU629316B2 (en) * 1990-04-11 1992-10-01 Flora Inc. Periodontal disease treatment system
US6902743B1 (en) * 1995-05-22 2005-06-07 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix
US6132759A (en) * 1996-05-03 2000-10-17 Innogenetics N.V. Medicaments containing gelatin cross-linked with oxidized polysaccharides
CA2253980C (en) * 1996-05-23 2004-08-17 Samyang Corporation Locally administrable, biodegradable and sustained-release pharmaceutical composition for periodontitis and process for preparation thereof
US6515016B2 (en) * 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US5861149A (en) 1997-06-04 1999-01-19 Polyheal Ltd. Methods for wound treatment
CN1507357A (zh) * 2000-10-31 2004-06-23 PRҩƷ���޹�˾ 提高生物活性分子传递的方法和组合物
CU23043A1 (es) 2001-12-20 2005-05-20 Ct Ingenieria Genetica Biotech Composicion farmaceutica que contiene factor de crecimiento epidrmico (egf) para la prevencion de la amputacion de pie diabetico.
EP1482966B1 (en) 2002-03-12 2014-05-14 Bio-Click Technologies Ltd Method and composition for treating skin wounds with epidermal growth factor
CN1720989A (zh) * 2004-07-15 2006-01-18 深圳市清华源兴生物医药科技有限公司 一种表皮生长因子缓释微球及其制备方法与应用
CU23411B6 (es) 2005-12-29 2009-09-08 Ct Ingenieria Genetica Biotech Uso tópico del factor de crecimiento epidérmico en liposomas para prevenir la amputación del pie diabético

Also Published As

Publication number Publication date
AU2007211753A1 (en) 2007-08-09
EP1987817B1 (en) 2009-07-29
DE602007001786D1 (de) 2009-09-10
CN103933552A (zh) 2014-07-23
AU2007211753B2 (en) 2012-03-01
WO2007087759A2 (es) 2007-08-09
EP1987817A2 (en) 2008-11-05
DK1987817T3 (da) 2009-11-30
SG169366A1 (en) 2011-03-30
KR101401273B1 (ko) 2014-05-29
CU23388B6 (es) 2009-07-16
RU2008135354A (ru) 2010-03-10
JP2009525288A (ja) 2009-07-09
BRPI0707395A2 (pt) 2011-05-03
WO2007087759A3 (es) 2007-09-20
ZA200806648B (en) 2009-05-27
KR20080096804A (ko) 2008-11-03
RU2426528C2 (ru) 2011-08-20
US8741848B2 (en) 2014-06-03
AR059234A1 (es) 2008-03-19
PL1987817T3 (pl) 2010-01-29
ES2330688T3 (es) 2009-12-14
JP5219841B2 (ja) 2013-06-26
CY1109513T1 (el) 2014-08-13
MY143742A (en) 2011-07-15
ATE437631T1 (de) 2009-08-15
CA2640743A1 (en) 2007-08-09
CA2640743C (en) 2012-05-15
SI1987817T1 (sl) 2009-12-31
HK1198743A1 (en) 2015-06-05
US20090220608A1 (en) 2009-09-03
PT1987817E (pt) 2009-10-26

Similar Documents

Publication Publication Date Title
AU2007211753B2 (en) Pharmaceutical composition of microspheres for preventing diabetic foot amputation
Wang et al. Effects of topical insulin on wound healing: a review of animal and human evidences
Kong et al. Biomimetic hydrogel for rapid and scar-free healing of skin wounds inspired by the healing process of oral mucosa
Cevher et al. Characterization of biodegradable chitosan microspheres containing vancomycin and treatment of experimental osteomyelitis caused by methicillin-resistant Staphylococcus aureus with prepared microspheres
Jiang et al. Dual delivery of chlorhexidine and platelet-derived growth factor-BB for enhanced wound healing and infection control
Lee et al. Local and sustained vascular endothelial growth factor delivery for angiogenesis using an injectable system
RU2357725C2 (ru) Фармацевтическая композиция для топикального применения в форме ксерогелей или пленок и способы производства
US20200197286A1 (en) Soluble microneedle for delivering proteins or peptides
US20220331492A1 (en) Composition and method for controlled drug release from a tissue
Sun et al. Vancomycin-loaded in situ gelled hydrogel as an antibacterial system for enhancing repair of infected bone defects
Aghazadeh et al. Vancomycin prolonged release via PLGA system loaded with drug-containing chitosan nanoparticles as a novel in situ forming drug delivery system
CN101198348A (zh) 骨形态发生蛋白制剂
AU2006331223B2 (en) Use of a topical composition containing epidermal growth factor (EGF) for diabetic foot amputation prevention
Wassif et al. Recent Advances in the Local Drug Delivery Systems for Diabetic Wound Healing: A Comprehensive Review
Umeki et al. Preparation and evaluation of biodegradable microspheres containing a new potent osteogenic compound and new synthetic polymers for sustained release
Liu et al. Poly (lactic-co-glycolic acid)-Chitosan–gelatin composite nanomaterials for the treatment of diabetic foot ulcer wound infection
Baysal et al. Nanoparticles and nanostructured films with TGF-β3: preparation, characterization, and efficacy
MX2008009943A (en) Pharmaceutical composition of microspheres for preventing diabetic foot amputation
HK1130681A (en) Pharmaceutical composition of microspheres for preventing diabetic foot amputation
TW201714610A (zh) 蛋白質或肽傳遞用的可溶性微針
JP2001316282A (ja) 生理活性ペプチド含有コラーゲン成形体及びその製法
US20220211683A1 (en) Novel material for skin wound closure and scar prevention
DK1970071T3 (en) USE OF A TOPICAL COMPOSITION CONTAINING epidermal growth factor (Epidermal Growth Factor - EGF) FOR PREVENTION OF DIABETIC FODAMPUTATION
US20160256565A1 (en) Composite bioabsorbable barrier membranes with sustained dual drug delivery for tissue engineering and guided tissue regeneration

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1130681

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20090401

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1130681

Country of ref document: HK